CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will join the H.C.
Rhea-AI Summary
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will join the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Management will host a virtual fireside chat and one-on-one investor meetings on Monday, June 15, 2026, with a webcast available via the company’s investor section.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRVO
On Jun 12, the day this news came out, CRVO closed 0.41% above the previous close.
Data tracked by StockTitan Argus for the Jun 12 session.
Key Figures
- Conference edition
- 7th Annual
- H.C. Wainwright Neuro Perspectives Expert Summit
- Presentation date
- June 15, 2026
- Virtual summit fireside chat
- Presentation time
- 7:00–7:30 AM ET
- Scheduled fireside chat window
Historical Context
-
Private placement to raise $10.5M and fund neflamapimod toward Phase 3.
-
Q1 2026 results with $12.9M cash and $8.0M net loss disclosed.
-
Phase 2b MRI data showing basal forebrain volume and connectivity benefits.
-
Neflamapimod program update and biomarker data at LBDA annual meeting.
-
AD/PD 2026 data highlighting greater benefit in low pTau181 DLB subgroup.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.
Presentation Details
Format: Fireside Chat
Date: Monday, June 15, 2026
Time: 7:00 – 7:30 AM ET
Webcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.